NASDAQ:SYRE

Spyre Therapeutics Stock News

Healthcare > Biotechnology

Buy SYRE

*Your capital is at risk

$93.73

-4.01 (-4.10%)

At Close: Jul 13, 2026

Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors

07:30am, Monday, 05'th Feb 2024

WALTHAM, Mass. , Feb. 5, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering

Spyre Therapeutics Announces Grants of Inducement Awards

05:30pm, Friday, 02'nd Feb 2024

WALTHAM, Mass. , Feb. 2, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering

Spyre Therapeutics Announces Grants of Inducement Awards

05:00pm, Friday, 22'nd Dec 2023

WALTHAM, Mass. , Dec. 22, 2023 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform

Spyre Therapeutics Announces $180 Million Private Placement

06:20pm, Thursday, 07'th Dec 2023

WALTHAM, Mass. , Dec. 7, 2023 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform t

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by